Press Releases
MAPS PBC Announces Publication of Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for PTSD in Nature Medicine
Study met primary and secondary endpoints confirming first Phase 3 study findings MAPP2 population reflects PTSD demographic with approximately half of study participants identifying as racially or ethnically diverse Company on track for NDA filing in 2023 SAN JOSE,...
American Medical Association Published Language for New Codes for Psychedelic-Assisted Therapies
Codes will provide qualified healthcare professionals a means to seek reimbursement for delivering MDMA-assisted therapy if it is approved by the U.S. Food and Drug Administration SAN JOSE, Calif., July 6, 2023—MAPS Public Benefit Corporation (“MAPS PBC”), a...
MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD
Agreement underscores benefit of collaboration to accelerate review of new evidence-based treatment options for people with PTSD Submission of new drug application expected in the second half of 2023 SAN JOSE, Calif., June 21, 2023—MAPS Public Benefit Corporation...
American Medical Association to Issue First New Code for Psychedelic Therapies
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved London, UK and San Jose, US – May 2, 2023 COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company...
MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD SAN...
MAPS PBC Announces Frontiers in Psychiatry Published First Study to Evaluate Neural Impact of MDMA-Assisted Therapy in Patients with PTSD
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...
MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA group If approved, MAPS PBC’s MDMA-assisted therapy could be the...
MAPS PBC Completes Second Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif., November 17, 2022—MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development...
MAPS PBC Elects Jeff George as Chairman of the Board of Directors
The new chairman brings critical commercial expertise and pharmaceutical leadership needed during MAPS PBC’s growth phase MDMA-assisted therapy, a novel treatment for post-traumatic stress disorder (PTSD) with FDA breakthrough therapy designation, is on track for new...
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System This essential proof-of-principle study tests safety and...